Second-line therapy for esophageal cancer

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer83(1), 18–29 (1999).
   PubMed Web of Science ®Google Scholar
• Ajani J, Bekaii-Saab T, D’Amico TA et al. Esophageal Cancer Clinical Practice Guidelines. J. Natl Compr. Canc. Netw.4(4), 328–347 (2006).
   Google Scholar
• Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol.17(1), 2–9 (2007).
   PubMed Web of Science ®Google Scholar
• Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer83(10), 2049–2053 (1998).
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Mayer RJ. Esophageal cancer. N. Engl. J. Med.349(23), 2241–2252 (2003).
   PubMed Web of Science ®Google Scholar
• Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control4(2), 123–132 (1993).
   PubMed Web of Science ®Google Scholar
• Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann. Surg.234(3), 360–367 (2001).
   PubMed Web of Science ®Google Scholar
• Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann. Surg.232(3), 353–361 (2000).
   PubMed Web of Science ®Google Scholar
• Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago–gastric junction: relevance of a topographic–anatomic subclassification. J. Surg. Oncol.90(3), 139–146 (2005).
   PubMed Web of Science ®Google Scholar
• Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC. A Phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer78(10), 2070–2077 (1996).
   PubMed Web of Science ®Google Scholar
• Petrasch S, Welt A, Reinacher A, Graeven U, Konig M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br. J. Cancer78(4), 511–514 (1998).
   PubMed Web of Science ®Google Scholar
• Ilson DH, Saltz L, Enzinger P et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol.17(10), 3270–3275 (1999).
   PubMed Web of Science ®Google Scholar
• Bleiberg H, Conroy T, Paillot B et al. Randomised Phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur. J. Cancer33(8), 1216–1220 (1997).
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol.15(1), 261–267 (1997).
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol.20(8), 1996–2004 (2002).
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Norman A, Cunningham D et al. A multicentre, randomised Phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann. Oncol.13(10), 1568–1575 (2002).
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer72(1), 37–41 (1993).
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol.8(2), 163–168 (1997).
   PubMed Web of Science ®Google Scholar
• Nicolaou N, Conlan AA. Cyclophosphamide, doxorubicin and celestin intubation for inoperable oesophageal carcinoma. S. Afr. Med. J.61(12), 428–431 (1982).
   PubMed Web of Science ®Google Scholar
• Levard H, Pouliquen X, Hay JM et al. 5-fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur. J. Surg.164(11), 849–857 (1998).
   PubMedGoogle Scholar
• Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin. Oncol.26(Suppl. 15), 12–20 (1999).
   PubMed Web of Science ®Google Scholar
• Fenchel K, Karthaus M, Steffens C et al. Taxanes. An effective 2nd line treatment of advanced esophageal cancer: a randomised trial. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract 1088).
   Google Scholar
• Metges J-P, Hennequin C, Ychou M et al. Docetaxel (DOC) as a second line chemotherapy in metastatic esophageal cancer (MEC): a French Study. Proc. Am. Soc. Clin. Oncol.20 (2001) (Abstract 635).
   Google Scholar
• Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest. New Drugs20(1), 95–99 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson SE, O’Reilly EM, Kelsen DP, Ilson DH. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest.21(4), 512–516 (2003).
   PubMed Web of Science ®Google Scholar
• Muro K, Hamaguchi T, Ohtsu A et al. A Phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann. Oncol.15, 955–959 (2004).
   PubMed Web of Science ®Google Scholar
• Conroy T, Etienne PL, Adenis A et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J. Clin. Oncol.14(1), 164–170 (1996).
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer final results of a Phase II trial. Br. J. Cancer92(12), 2129–2133 (2005).
   PubMedGoogle Scholar
• Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res.4(4), 1013–1019 (1998).
   PubMed Web of Science ®Google Scholar
• Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis. Esophagus19(6), 473–476 (2006).
   Google Scholar
• Mafune K, Yamada K, Imamura K, Kubota M, Kaminishi M. Docetaxel, 5-fluorouracil and nedaplatin as second-line chemotherapy for patients with esophageal cancer after esophagectomy: a pilot study. Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 4140).
   Google Scholar
• Lordick F, Von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory esophageal cancer. Br. J. Cancer89(4), 630–633 (2003).
   PubMed Web of Science ®Google Scholar
• Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al. Predictive factors for outcome in a Phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J. Clin. Oncol.24(10), 1612–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Rybicki LA, Carroll MA, Rice TW, Mekhail T. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. Proc. Am. Soc. Clin. Oncol.23 (2005) (Abstract 4054).
   Google Scholar
• Tew WP, Shah M, Schwartz G, Kelsen D, Ilson DH. Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Presented at: Gastrointestinal Cancers Symposium Hollywood, Florida, 27–29 January 2005 (Abstract 49A).
   Google Scholar
• Shah MA, Ramanathan RK, Ilson DH et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol.24(33), 5201–5206 (2006).
   PubMed Web of Science ®Google Scholar